- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Matthew Gubens: Multidisciplinary Approach Can Help Oncologists Tackle Immunotherapy Toxicities
When employing immunotherapies, oncologists must be vigilant in spotting any adverse events and calling in their colleagues, like dermatologists or pulmonologists, to help manage these toxicities, according to Matthew Gubens, MD, MS, assistant clinical professor of thoracic oncology at the University of California, San Francisco.
When employing immunotherapies, oncologists must be vigilant in spotting any adverse events and calling in their colleagues, like dermatologists or pulmonologists, to help manage these toxicities, according to Matthew Gubens, MD, MS, assistant clinical professor of thoracic oncology at the University of California, San Francisco.
Transcript (slightly modified)
What are some of the toxicity concerns with immunotherapy and how can they be managed?
One of the exciting things about oncology is we’re such a multidisciplinary field. We’re really used to working in tumor boards, medical oncology, surgical oncology, pathology, radiology. These drugs are really forcing us to look even further abroad. We’re really looking at working with our endocrinologists, our pulmonologists, our rheumatologists, because some of these immune adverse events [AEs] are really coming to the fore, things that oncologists haven’t had to deal with medically.
I think there are 2 questions. One is, for patient selection for these agents, can you give these drugs to patients who have autoimmune disease, and we’re trying to suss that out. Folks who have long-standing hypothyroidism, not a problem. Patients with active ulcerative colitis, certainly we can’t use them.
But then of course the question is, after they’ve been treated, how do we handle that? First and foremost, it’s just recognition, anticipation and recognition. Certainly we do thyroid function tests very regularly throughout the course of treatment. We’re very attuned to changes in oxygenation that may portend pneumonitis, and then we’re really quick to, when we see those kind of changes, engaging our colleagues. So if there’s a rash, we have dermatologists who are savvy about these and help us to manage them.
Really, the name of the game is making sure we handle these AEs so that patients who are benefiting can continue to benefit and not have the morbidity or even mortality of some of these side effects.
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
October 21st 2024Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Ways Providers, Payers Can Ensure Biomarker Testing Is Done in Cancer Care
October 18th 2024There is a role for both payers and providers to make small changes that would increase the use of biomarker testing to ensure patients are receiving the appropriate treatment, said Susan Wescott, RPh, MBA, senior director of managed care pharmacy, Mayo Clinic.
Read More
